PROVIDER HEALTH ADVISORY

Date: March 22, 2021  
Contact: Rick Rosen, MD, MPH (805)781-5500, frosen@co.slo.ca.us

CDPH Directs Facilities to Stop Administration of Bamlanivimab Monotherapy in California

On Friday, March 19, 2021, the California Department of Public Health (CDPH) issued a Health Alert directing all facilities in California to discontinue the administration of bamlanivimab monotherapy effective immediately.

Bamlanivimab is an investigational monoclonal antibody product that received emergency use authorization from the U.S. Food and Drug Administration in November 2020 for the treatment of mild to moderate COVID-19 with high risk of progression to severe disease. However, evidence suggests that bamlanivimab demonstrates reduced clinical effectiveness against the B.1.427 and B.1.429 variants of SARS-CoV2 (the “West Coast variants”).

Bamlanivimab used in combination with etesevimab is still recommended and believed to be clinically effective against the West Coast variants. The combination of casirivimab plus imdevimab is an alternative monoclonal antibody treatment option believed to be effective against B.1.427 and B.1.429.

For more information regarding bamlanivimab and the use of monoclonal antibodies in the treatment of COVID-19, please see the attached Health Alert from CDPH.